These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 24114522)

  • 1. Somatic copy number alterations by whole-exome sequencing implicates YWHAZ and PTK2 in castration-resistant prostate cancer.
    Menon R; Deng M; Rüenauver K; Queisser A; Peifer M; Pfeifer M; Offermann A; Boehm D; Vogel W; Scheble V; Fend F; Kristiansen G; Wernert N; Oberbeckmann N; Biskup S; Rubin MA; Adler D; Perner S
    J Pathol; 2013 Dec; 231(4):505-16. PubMed ID: 24114522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.
    Beltran H; Yelensky R; Frampton GM; Park K; Downing SR; MacDonald TY; Jarosz M; Lipson D; Tagawa ST; Nanus DM; Stephens PJ; Mosquera JM; Cronin MT; Rubin MA
    Eur Urol; 2013 May; 63(5):920-6. PubMed ID: 22981675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exome enrichment and SOLiD sequencing of formalin fixed paraffin embedded (FFPE) prostate cancer tissue.
    Menon R; Deng M; Boehm D; Braun M; Fend F; Boehm D; Biskup S; Perner S
    Int J Mol Sci; 2012; 13(7):8933-8942. PubMed ID: 22942743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrative molecular profiling reveals asparagine synthetase is a target in castration-resistant prostate cancer.
    Sircar K; Huang H; Hu L; Cogdell D; Dhillon J; Tzelepi V; Efstathiou E; Koumakpayi IH; Saad F; Luo D; Bismar TA; Aparicio A; Troncoso P; Navone N; Zhang W
    Am J Pathol; 2012 Mar; 180(3):895-903. PubMed ID: 22245216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrative molecular profiling of routine clinical prostate cancer specimens.
    Grasso CS; Cani AK; Hovelson DH; Quist MJ; Douville NJ; Yadati V; Amin AM; Nelson PS; Betz BL; Liu CJ; Knudsen KE; Cooney KA; Feng FY; McDaniel AS; Tomlins SA
    Ann Oncol; 2015 Jun; 26(6):1110-1118. PubMed ID: 25735316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of YWHAZ expression in localized prostate cancer.
    Rüenauver K; Menon R; Svensson MA; Carlsson J; Vogel W; Andrén O; Nowak M; Perner S
    Prostate Cancer Prostatic Dis; 2014 Dec; 17(4):310-4. PubMed ID: 25156059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Muscarinic receptors promote castration-resistant growth of prostate cancer through a FAK-YAP signaling axis.
    Goto Y; Ando T; Izumi H; Feng X; Arang N; Gilardi M; Wang Z; Ando K; Gutkind JS
    Oncogene; 2020 May; 39(20):4014-4027. PubMed ID: 32205868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of somatic copy number alterations in cancer using targeted exome capture sequencing.
    Lonigro RJ; Grasso CS; Robinson DR; Jing X; Wu YM; Cao X; Quist MJ; Tomlins SA; Pienta KJ; Chinnaiyan AM
    Neoplasia; 2011 Nov; 13(11):1019-25. PubMed ID: 22131877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PTEN deletion and heme oxygenase-1 overexpression cooperate in prostate cancer progression and are associated with adverse clinical outcome.
    Li Y; Su J; DingZhang X; Zhang J; Yoshimoto M; Liu S; Bijian K; Gupta A; Squire JA; Alaoui Jamali MA; Bismar TA
    J Pathol; 2011 May; 224(1):90-100. PubMed ID: 21381033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Common structural and epigenetic changes in the genome of castration-resistant prostate cancer.
    Friedlander TW; Roy R; Tomlins SA; Ngo VT; Kobayashi Y; Azameera A; Rubin MA; Pienta KJ; Chinnaiyan A; Ittmann MM; Ryan CJ; Paris PL
    Cancer Res; 2012 Feb; 72(3):616-25. PubMed ID: 22158653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dysregulation of the splicing machinery is directly associated to aggressiveness of prostate cancer.
    Jiménez-Vacas JM; Herrero-Aguayo V; Montero-Hidalgo AJ; Gómez-Gómez E; Fuentes-Fayos AC; León-González AJ; Sáez-Martínez P; Alors-Pérez E; Pedraza-Arévalo S; González-Serrano T; Reyes O; Martínez-López A; Sánchez-Sánchez R; Ventura S; Yubero-Serrano EM; Requena-Tapia MJ; Castaño JP; Gahete MD; Luque RM
    EBioMedicine; 2020 Jan; 51():102547. PubMed ID: 31902674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ERG protein expression and gene rearrangements are present at lower rates in metastatic and locally advanced castration-resistant prostate cancer compared to localized disease.
    Teng LH; Wang C; Bégin LR; Dolph M; Yilmaz A; Trpkov K; Donnelly B; Bismar TA
    Urology; 2013 Aug; 82(2):394-9. PubMed ID: 23746715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and Development of a Fully Synthetic Multiplex Ligation-Dependent Probe Amplification-Based Probe Mix for Detection of Copy Number Alterations in Prostate Cancer Formalin-Fixed, Paraffin-Embedded Tissue Samples.
    Ebrahimizadeh W; Guérard KP; Rouzbeh S; Bramhecha YM; Scarlata E; Brimo F; Patel PG; Jamaspishvili T; Aprikian AG; Berman D; Bartlett JMS; Chevalier S; Lapointe J
    J Mol Diagn; 2020 Oct; 22(10):1246-1263. PubMed ID: 32763409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrative Exome Sequencing Analysis in Castration-Resistant Prostate Cancer in Chinese Population.
    Hao L; Li H; Zhang S; Yang Y; Xu Z; Zhang Y; Liu Z
    Curr Pharm Biotechnol; 2020; 21(2):140-148. PubMed ID: 31580249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression screening of cancer/testis genes in prostate cancer identifies NR6A1 as a novel marker of disease progression and aggressiveness.
    Mathieu R; Evrard B; Fromont G; Rioux-Leclercq N; Godet J; Cathelineau X; Guillé F; Primig M; Chalmel F
    Prostate; 2013 Jul; 73(10):1103-14. PubMed ID: 23532770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Y-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expression.
    Shiota M; Takeuchi A; Song Y; Yokomizo A; Kashiwagi E; Uchiumi T; Kuroiwa K; Tatsugami K; Fujimoto N; Oda Y; Naito S
    Endocr Relat Cancer; 2011 Aug; 18(4):505-17. PubMed ID: 21652770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The mutational landscape of lethal castration-resistant prostate cancer.
    Grasso CS; Wu YM; Robinson DR; Cao X; Dhanasekaran SM; Khan AP; Quist MJ; Jing X; Lonigro RJ; Brenner JC; Asangani IA; Ateeq B; Chun SY; Siddiqui J; Sam L; Anstett M; Mehra R; Prensner JR; Palanisamy N; Ryslik GA; Vandin F; Raphael BJ; Kunju LP; Rhodes DR; Pienta KJ; Chinnaiyan AM; Tomlins SA
    Nature; 2012 Jul; 487(7406):239-43. PubMed ID: 22722839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Whole exome sequencing (WES) on formalin-fixed, paraffin-embedded (FFPE) tumor tissue in gastrointestinal stromal tumors (GIST).
    Astolfi A; Urbini M; Indio V; Nannini M; Genovese CG; Santini D; Saponara M; Mandrioli A; Ercolani G; Brandi G; Biasco G; Pantaleo MA
    BMC Genomics; 2015 Nov; 16():892. PubMed ID: 26531060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ASC-J9® suppresses prostate cancer cell proliferation and invasion via altering the ATF3-PTK2 signaling.
    Tian H; Chou FJ; Tian J; Zhang Y; You B; Huang CP; Yeh S; Niu Y; Chang C
    J Exp Clin Cancer Res; 2021 Jan; 40(1):3. PubMed ID: 33390173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Next-generation sequencing of RNA and DNA isolated from paired fresh-frozen and formalin-fixed paraffin-embedded samples of human cancer and normal tissue.
    Hedegaard J; Thorsen K; Lund MK; Hein AM; Hamilton-Dutoit SJ; Vang S; Nordentoft I; Birkenkamp-Demtröder K; Kruhøffer M; Hager H; Knudsen B; Andersen CL; Sørensen KD; Pedersen JS; Ørntoft TF; Dyrskjøt L
    PLoS One; 2014; 9(5):e98187. PubMed ID: 24878701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.